Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Flow cytometric analysis of Alexa Fluor® 647 anti-human IL-17A on stimulated PBMC. Human PBMC were stimulated with PMA/Ionomycin in the presence of BD GolgiStop™ (Cat. No. 554724) for 5 hours. Cells were then fixed and permeabilized using BD Cytofix/Cytoperm™ reagents (Cat. No. 554714) followed by staining with Alexa Fluor® 647 anti-human IL-17A and FITC anti-human IFN-γ (Cat. No. 554700; left panel) and PE anti-human IL-4 (Cat. No. 554485; right panel). The dot plots were derived from a lymphocyte gate. Flow cytometry was performed on a BD FACSCalibur™ System.
Flow cytometric analysis of Alexa Fluor® 647 anti-human IL-17A on stimulated PBMC. Human PBMC were stimulated with PMA/Ionomycin in the presence of BD GolgiStop™ (Cat. No. 554724) for 5 hours. Cells were then fixed and permeabilized using BD Cytofix/Cytoperm™ reagents (Cat. No. 554714) followed by staining with Alexa Fluor® 647 anti-human IL-17A and FITC anti-human IFN-γ (Cat. No. 554700; left panel) and PE anti-human IL-4 (Cat. No. 554485; right panel). The dot plots were derived from a lymphocyte gate. Flow cytometry was performed on a BD FACSCalibur™ System.
Flow cytometric analysis of Alexa Fluor® 647 anti-human IL-17A on stimulated PBMC. Human PBMC were stimulated with PMA/Ionomycin in the presence of BD GolgiStop™ (Cat. No. 554724) for 5 hours. Cells were then fixed and permeabilized using BD Cytofix/Cytoperm™ reagents (Cat. No. 554714) followed by staining with Alexa Fluor® 647 anti-human IL-17A and FITC anti-human IFN-γ (Cat. No. 554700; left panel) and PE anti-human IL-4 (Cat. No. 554485; right panel). The dot plots were derived from a lymphocyte gate. Flow cytometry was performed on a BD FACSCalibur™ System.
Flow cytometric analysis of Alexa Fluor® 647 anti-human IL-17A on stimulated PBMC. Human PBMC were stimulated with PMA/Ionomycin in the presence of BD GolgiStop™ (Cat. No. 554724) for 5 hours. Cells were then fixed and permeabilized using BD Cytofix/Cytoperm™ reagents (Cat. No. 554714) followed by staining with Alexa Fluor® 647 anti-human IL-17A and FITC anti-human IFN-γ (Cat. No. 554700; left panel) and PE anti-human IL-4 (Cat. No. 554485; right panel). The dot plots were derived from a lymphocyte gate. Flow cytometry was performed on a BD FACSCalibur™ System.
Flow cytometric analysis of Alexa Fluor® 647 anti-human IL-17A on stimulated PBMC. Human PBMC were stimulated with PMA/Ionomycin in the presence of BD GolgiStop™ (Cat. No. 554724) for 5 hours. Cells were then fixed and permeabilized using BD Cytofix/Cytoperm™ reagents (Cat. No. 554714) followed by staining with Alexa Fluor® 647 anti-human IL-17A and FITC anti-human IFN-γ (Cat. No. 554700; left panel) and PE anti-human IL-4 (Cat. No. 554485; right panel). The dot plots were derived from a lymphocyte gate. Flow cytometry was performed on a BD FACSCalibur™ System.
Flow cytometric analysis of Alexa Fluor® 647 anti-human IL-17A on stimulated PBMC. Human PBMC were stimulated with PMA/Ionomycin in the presence of BD GolgiStop™ (Cat. No. 554724) for 5 hours. Cells were then fixed and permeabilized using BD Cytofix/Cytoperm™ reagents (Cat. No. 554714) followed by staining with Alexa Fluor® 647 anti-human IL-17A and FITC anti-human IFN-γ (Cat. No. 554700; left panel) and PE anti-human IL-4 (Cat. No. 554485; right panel). The dot plots were derived from a lymphocyte gate. Flow cytometry was performed on a BD FACSCalibur™ System.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Human IL-17A, also known as IL-17, is a proinflammatory cytokine that is encoded by the IL17A gene in chromosome 6. IL-17A is produced as a disulfide-linked homodimer comprised of two mature 136-amino acid polypeptides. It is a member of the IL-17 family of structurally related cytokines, designated IL-17A through IL-17F. Activated memory T cells, especially Th17 cells (specialized IL-17A-producing CD4+ T cells distinct from Th1 and Th2 cells) produce IL-17 and provide protective immunity against pathogens. Activated CD8+ T cells, γδT cells, NK cells and neutrophils can also be activated to produce IL-17A. IL-17A binds to and exerts its biological activity through IL-17 receptors (IL-17R) that are expressed by a variety of target cells including fibroblasts, epithelial and endothelial cells, monocytes/macrophages and mast cells. The ubiquitous IL-17R expression pattern may explain the broad tissue responsiveness to IL-17. IL-17 induces stromal cells to secrete cytokines and chemokines involved in inflammatory and hematopoietic processes. For example, IL-17 induces fibroblasts to produce IL-6, IL-8, G-CSF and express increased surface ICAM-1. The N49-653 antibody reacts with human IL-17A.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.